Vaxinano is changing scale. The Lille-based biotech, which has validated its Stellar-NP platform...
News
Vaxinano and ECO Animal Health Sign Exclusive Licensing Agreement for Toxoplasmosis Vaccine
Vaxinano is pleased to announce the signing of an exclusive licensing agreement with ECO Animal...
Field Evidence Highlights the Potential of VXN-Toxo Against Toxoplasmosis in Captive Wildlife
Proud to share a new testimony highlighting the impact and importance of VXN-Toxo. VXN-Toxo is an...
Vaxinano Shares Latest Vaccine Immunology Advances at Colloque I3M
Vaxinano was proud to participate in the latest edition of the Colloque I3M, where the team shared...
Vaxinano Receives France 2030 Innovation Support
We are proud to announce that Vaxinano has been selected as a winner of the INOV State Innovation...
Vaxinano at NIVI: Advancing the Future of Mucosal Vaccines Through Airway Immunity
Honored that Didier Betbeder, our CSO, was invited to present the Vaxinano mucosal vaccine...
“Impact” Award at Tech For Future
Vaxinano Wins the "Impact" Award at Tech For Future by La...
Vaxinano Announces Exclusive Licensing Agreement with Vetoquinol
October 2024 – Today, Vaxinano announced an exclusive license agreement with Vetoquinol to develop...
Vaxinano Secures €6 Million in Funding to Advance Nasal Vaccines to Clinical Trials
Vaxinano, sept 25th 2024, Lille- France : Vaxinano Secures €6 Million in Funding to Advance Nasal...
Video Vaxinano STELLAR-NP
Title: Pioneering Vaccine Solutions with Vaxinano’s STELLAR-NP Platform Description:Vaxinano is...
Program of Vaccination at the Pairi Daiza Zoo
Vaxinano's vaccine is presented in the Pairi Daiza Zoo collaboration For several years, we have...
International Biodiveristy Day
Our ONE Health mission is to protect all animals and all humans around the world. And we are...
Conference Animal Health, Nutrition and Technology Innovation
Vaxinano presents latest vaccine research and development activities to the Animal Health,...
Ocular Toxoplasmosis Vaccine for South America
Ocular Toxoplasmosis is a public health problem across south america. In Colombia, 6% of the...
Green Light for importation of our Toxoplasmosis vaccine in Mexico!
We are thrilled to announce that the Mexican government has granted approval for the importation...
Paroles d’Experts Vaxinano : La biotechnologie dans le domaine du vaccin
Paroles d'Experts Vaxinano : La biotechnologie dans le domaine du vaccin Ce numéro de Paroles...
100 start-up où investir en 2019
Vaxinano : des vaccins sans adjuvant et sans aiguille Vaxinano développe des vaccins sûrs, plus...
Vaxinano peaufine son vaccin sans adjuvant administré par voie nasale
Vaxinano peaufine son vaccin sans adjuvant administré par voie nasale Développant des vaccins sans...
Vaxinano is developing the first vaccine against toxoplasmosis
Founded in July 2016 within the Eurasanté bio-incubator in Lille, Vaxinano is developing the first...